AGRX - Agile Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 568.79M
Enterprise Value 341.6M
Trailing P/E N/A
Forward P/E 1-4.30
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)2.24
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-2.79

Trading Information

Stock Price History

Beta (3Y Monthly) -0.48
52-Week Change 3247.06%
S&P500 52-Week Change 32.99%
52 Week High 31.7000
52 Week Low 30.3230
50-Day Moving Average 31.1868
200-Day Moving Average 31.3449

Share Statistics

Avg Vol (3 month) 3500.82k
Avg Vol (10 day) 3895.14k
Shares Outstanding 559.3M
Float 30.97M
% Held by Insiders 11.27%
% Held by Institutions 154.21%
Shares Short (Aug 15, 2019) 4268.72k
Short Ratio (Aug 15, 2019) 40.59
Short % of Float (Aug 15, 2019) 40.92%
Short % of Shares Outstanding (Aug 15, 2019) 40.45%
Shares Short (prior month Jul 15, 2019) 4346.26k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-30.46%
Return on Equity (ttm)-63.89%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -14.9M
Net Income Avi to Common (ttm)-15.76M
Diluted EPS (ttm)-0.4200
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)10.59M
Total Cash Per Share (mrq)0.24
Total Debt (mrq)249k
Total Debt/Equity (mrq)1.08
Current Ratio (mrq)6.07
Book Value Per Share (mrq)0.52

Cash Flow Statement

Operating Cash Flow (ttm)-14.33M
Levered Free Cash Flow (ttm)-8.26M